Therapeutic modulation of NRP2 has been discussed for myelofibrosis (56) and has shown promise in late-stage clinical trials for pulmonary fibrosis in sarcoidosis patients (55), where the possible mechanism of action of the NRP2 agent Efzofitimod is to reduce pro-inflammatory macrophages and to prevent the progression of pulmonary fibrosis (55). The gene discussed is NRP2; the disease is pulmonary fibrosis.